SCHEMBL6499989

SCHEMBL6499989

Cc1ccc(C2=C(C(=O)Nc3ccc(N4CCNCC4)cc3)CCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
MAPT P10636 4/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
MCL1 Q07820 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 2/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPKAPK2 P49137 9/20 0.51
IRAK4 Q9NWZ3 1/20 0.50
ADRB1 P08588 1/20 0.49
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 3/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496056 0.86 MAPKAPK2 (0.66) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL6501524 0.84 L3MBTL1 (0.53) RAB9AMAPTKDM4EL3MBTL1IRAK4
SCHEMBL6502650 0.81 MAPT (0.47) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL6498772 0.81 MAPT (0.58) RAB9AMAPTKMT2AKDM4ESMN1; SMN2
SCHEMBL6488746 0.81 MAPT (0.60) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL6499900 0.80 DRD2 (0.46) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL6499147 0.80 MAPT (0.46) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL6491504 0.76 FAAH (0.49) RAB9AMAPTKMT2AKDM4ESMN1; SMN2
SCHEMBL6492454 0.76 MAPT (0.41) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL6504210 0.76 KMT2A (0.45) NPC1RAB9AMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NPC1 100/4885RAB9A 4382/4885MAPT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.